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Abstract
Background: Several studies have shown an association of cryptogenic stroke and embolism with patent foramen
ovale (PFO), but the question how to prevent further events in such patients is unresolved. Options include
antithrombotic treatment with warfarin or antiplatelet agents or surgical or endovascular closure of the PFO. The
PC-Trial was set up to compare endovascular closure and best medical treatment for prevention of recurrent
events.
Methods: The PC-Trial is a randomized clinical trial comparing the efficacy of percutaneous closure of the PFO
using the Amplatzer PFO occluder with best medical treatment in patients with cryptogenic embolism, i.e. mostly
cryptogenic stroke. Warfarin for 6 months followed by antiplatelet agents is recommended as medical treatment.
Randomization is stratified according to patients age (<45 versus ≥45 years), presence of atrial septal aneurysm
(ASA yes or no) and number of embolic events before randomization (one versus more than one event). Primary
endpoints are death, nonfatal stroke and peripheral embolism.
Discussion: patients were randomized in 29 centers of Europe, Canada, and Australia. Randomization started
February 2000. Enrollment of 414 patients was completed in February 2009. All patients will be followed-up
longitudinally. Follow-up is maintained until the last enrolled patient is beyond 2.5 years of follow-up (expected in
2011).
Trial Registration: Trial listed in ClinicalTrials.gov as NCT00166257 and sponsored by AGA Medical, Plymouth, MN,
USA
Introduction
The cause of ischemic stroke is considered cryptogenic in
35-40% of cases [1]. Paradoxical embolism can be the cause
of systemic embolism under all circumstances provided
there is a right to left shunt, but it is blamed for an embolic
event typically only in the absence of a left-sided throm-
boembolic source. Hence, paradoxical embolism via a
patent foramen ovale (PFO) is entertained in the differential
diagnosis especially in young patients (<60 years old) [2].
The detection of thrombus in the venous system or right
atrium is not to be considered a prerequisite as non-
detectable small clots are the most common culprits. Since
the direct detection of thrombus within a PFO is rare [3-6],
the diagnosis of paradoxical embolism is usually presump-
tive. While there is currently no proof for a cause-effect
relationship, several studies have confirmed a strong asso-
ciation between the presence of a PFO and the risk for
paradoxical embolism or stroke [7-11]. A PFO with a coin-
ciding atrial septal aneurysm (ASA), spontaneous or large
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right-to-left shunt, or multiple ischemic events potentiates
the risk of recurrence. [12]. The presence of a PFO or ASA
has currently no therapeutic consequence in otherwise
healthy adults. In contrast, patients suffering a stroke or
transient ischemic attack (TIA) in the presence of a PFO
are to be considered for medical therapy to reduce the risk
of a recurrent embolic event (secondary prevention).
Patients with PFO and ASA are defined as ‘high-risk’
patients for recurrent events. A retrospective French multi-
center study in such patients reported a yearly risk of 1.2%
to sustain a recurrent stroke and of 3.4% to suffer a recur-
rent stroke or TIA despite medical treatment with antipla-
telet drugs or oral anticoagulants in patients with PFO and
cryptogenic stroke [13]. In the Lausanne study no differ-
ences in risk reduction were noted between different
modes of anticoagulant therapy with respect to recurrent
stroke and TIA [14]. The Quality Standards Subcommittee
of the American Academy of Neurology recently published
evidence-based guidelines for the management of patients
with recurrent stroke, PFO, and ASA, after a critical review
of the literature [15]. Their main conclusion was that PFO
alone does not portend an increased risk of subsequent
stroke or death in patients who have had a cryptogenic
stroke and are treated medically [15]. There were insuffi-
cient data to draw conclusions about isolated ASA. The
results regarding patients with the combination of PFO and
ASA were somewhat inconsistent and did not allow draw-
ing conclusions for this subset of patients.
Nonsurgical closure of PFO has become possible with
the advent of implantable devices, and has long been
demonstrated feasible and safe [16,17]. It represents an
attractive treatment alternative to life-long antiplatelet
therapy or oral anticoagulation in patients with PFO
and paradoxical embolism.
The optimal treatment strategy of such symptomatic
patients remains to be defined, although nonrandomized
data suggest an advantage of percutaneous PFO closure
over medical treatment [18,19]. Thus the true therapeu-
tic efficacy of percutaneous PFO closure as an adjunct
or alternative to medical treatment needs to be ascer-
tained by randomized studies.
Methods
Rationale for the present study
While there is good evidence for the association
between the presence of PFO and the risk for paradoxi-
cal embolism, a cause-effect relationship has not been
conclusively established. Furthermore there are no pub-
lications of prospective, randomized studies comparing
the efficacy of different treatment modalities in patients
with PFO and paradoxical embolism including percuta-
neous device closure.
The purpose of the present study is to compare the effi-
cacy of percutaneous PFO closure using the Amplatzer
PFO Occluder (AGA Medical Corporation, Plymouth,
MN, USA), with medical treatment in patients with pre-
sumed paradoxical embolism in a prospective, randomized
trial.
Null-hypothesis to be rejected
Percutaneous device closure of PFO with the Amplatzer
PFO Occluder is of equal efficacy compared with medi-
cal treatment in the prevention of recurrent stroke and/
or TIA in patients with paradoxical embolism.
Design overview
This is a multicenter, multinational, randomized, clinical
trial comparing the efficacy of percutaneous PFO clo-
sure using the Amplatzer PFO Occluder with best medi-
cal treatment in patients with PFO and paradoxical
embolism. The organization and scientific conduct of
the study is supervised by a Steering Committee. A Data
and Safety Monitoring Board is responsible for safety
and ethical aspects. A Clinical Events Committee review
and adjudicate all reported adverse events and end-
points. Study monitoring and data management is car-
ried out by a contract research organization.
Study endpoints
The primary objective of this study is to investigate
whether percutaneous PFO closure using the Amplatzer
PFO Occluder is superior compared to best medical treat-
ment in the prevention of symptomatic, recurrent throm-
boembolism. The following combined primary endpoint
will therefore be assessed at each scheduled follow-up
visit: death, nonfatal stroke, and peripheral embolism.
Patients who experience a primary endpoint event
during the study period no longer have to continue the
treatment allocated at the time of randomization. The
management of patients who suffer a primary endpoint
event will be left to the discretion of the responsible
physician. Crossover from medical treatment to PFO
device closure or vice versa from PFO device closure to
additional antithrombotic treatment will be allowed in
case of a primary endpoint event. However, all patients
will continue to be followed up for further events after
an initial primary endpoint according to the study pro-
tocol for the total duration of this study. Appendix 1
details the primary and secondary endpoints.
Patient selection criteria
Patients with PFO and presumed paradoxical embolism
who meet all inclusion criteria but no exclusion criteria
of Appendices 2 and 3 are offered to participate in this
study. After obtaining a written informed consent,
patients were randomised in 29 centers of Europe,
Canada, and Australia. Randomization started February
2000. Enrolment of 414 patients was completed in
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February 2009. All patients will be followed-up longitud-
inally as outlined in Table 1. Follow-up is maintained
until the last enrolled patient is beyond 2.5 years of
follow-up (expected in 2011).
Treatment assignment
Randomization was done by a research contract organi-
zation (InterCorNet, Zurich, Switzerland) through com-
puter-generated block randomisation forms for each
participating centre. Patients were stratified according to
age (≥45 vs. <45 years) and presence or absence of ASA.
Percutaneous PFO closure was scheduled as soon as
possible following randomization. Implantation occurred
according to standard techniques by experienced opera-
tors familiar with the Amplatzer PFO Occluder.
Device
The device used for percutaneous PFO closure in
patients participating in the PC-trial was the Amplatzer
PFO Occluder, manufactured from 0.005” nitinol wire, a
superelastic shape memory alloy, which permits con-
straining of the device to a small (≤9 French) delivery sys-
tem with recovery of shape upon delivery in the atria. As
long as the device is screwed to its 0.038” delivery cable,
it is fully retrievable and repositionable without need for
removal of the device from the delivery sheath prior to a
new placement attempt. The device is available in differ-
ent sizes with typically the left atrial disk being smaller
than the right atrial disk (18 mm to 35 mm).
Implantation procedure
Patients scheduled for percutaneous PFO closure were
generally admitted on the day of the procedure and
discharged the same or following day. The procedure
was generally performed using local anesthesia. Balloon
gauging of the PFO was not encouraged. The decision
to guide device implantation by fluoroscopy only or use
simultaneous transesophegeal echocardiography (TEE)
or intracardiac echocardiography (ICE) was left to the
implanting physician. Prophylactic antibiotic therapy
(e.g. cephalosporin) was recommended during the peri-
procedural period followed by a recommendation for
prophylaxis against endocarditis for 2-6 months. Venous
access was typically established via the right femoral
vein. Femoral artery access was optional for invasive
blood pressure monitoring or to assess for coronary
artery disease by diagnostic coronary angiography. In
case of left-to-right shunt (small atrial septal defects)
balloon gauging and a complete right heart catheteriza-
tion with oximetry were recommended but not manda-
tory. After administration of systemic heparin (≥ 5000
IU) the PFO is probed, e.g. with a multipurpose catheter
or a standard (exchange) guidewire (0.035 inch). A 8-9
French Amplatzer sheath was used for device implanta-
tion. The Amplatzer PFO Occluder was delivered
through the delivery sheath and placed within the PFO
under fluoroscopic and optional echocardiographic gui-
dance. First, the usually smaller left atrial disc was
released in the left atrium. The whole unit consisting of
the sheath and the released left atrial disc was then
pulled gently against the interatrial septum. Following
this the right atrial disc was released by further with-
drawing the sheath, while maintaining some traction on
the interatrial septum with the left atrial disc. Care was
taken to avoid air embolism. After assurance of a stable
and correct device position (fluoroscopy with dye
Table 1 Timetable of prospective investigations during the study
Baseline Hospitalization 6
months
1
year
2
years
3
years
4
years
5
years
History x x x x x x x
Listing of antithrombotic medications x x x x x x x x
Laboratory survey x
12 lead ECG x x x x x x x x
Holter ECG x
TEE* x X (TTE or TEE) x (x)
CT/MR or angiography of region of interest (brain or periphery) x
Carotid Doppler x
Employment status x x x x x x x
Quality of life x x x x x x x
Stroke outcome classification (NIH SS, Barthel index, Modified
Rankin scale)
x x x x x x x x
Procedural complications x
Primary endpoints x x x x x x
Secondary endpoints x x x x x x
*TEE examination after 6 months and possibly yearly thereafter until complete closure of the PFO has been documented. A TEE at 5 years of follow-up or
termination of the study is optimal; a TTE is acceptable immediately following device closure.
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injection in a view showing the device in profile separat-
ing the 2 disks completely or echocardiography), the
device was released from the delivery cable. The final
position and eventual residual shunt were documented
by angiography or echocardiography. Following this, the
introducer sheath was removed and hemostasis assured
by applying manual compression to the access site.
Before hospital discharge stable device position was
documented by transthoracic echocardiography (TTE).
All implantation related complications were recorded as
adverse events.
A residual shunt is not unexpected immediately fol-
lowing device implantation. Subsequent endothelializa-
tion occurring over a few months improves the closure
rate. Completeness of closure for analysis was therefore
assessed by TEE with Valsalva followed by a bubble test
at 6 months of follow-up. All patients to be treated with
acetylsalicylic acid 100-325 mg/day for 5-6 months fol-
lowing device implantation. Ticlopidine 250-500 mg/day
or clopidogrel 75-150 mg/day, could be used comple-
mentary or as an alternative in case of intolerance to
acetylsalicylic acid. Oral anticoagulation was optional for
a period of 6 months, if deemed necessary by the inves-
tigator but was discouraged. Provided a satisfactory
result of the 6-month contrast TEE, antithrombotic
therapy and the recommendation for prophylaxis against
endocarditis were discontinued, unless required by
another indication.
Best medical treatment
Patients randomized to the best medical treatment arm
were not undergoing any catheterization procedure but
were treated with antithrombotic medication. Since
there is no consensus on the most effective medical
therapy in preventing recurrent stroke or TIA in
patients with PFO and paradoxical embolism, the choice
of antithrombotic therapy, either antiplatelet therapy or
oral anticoagulation, was left to the discretion of the
treating physician. However, all patients randomized to
the best medical treatment arm had to be treated with
at least one antithrombotic medication. The recom-
mended antithrombotic regimen in this study was oral
anticoagulation for a period of 6 months (to be com-
menced at the time of inclusion in the study), followed
by treatment with acetylsalicylic acid 100 mg to 325 mg
per day during the remainder of the study. However,
alternative treatment regimens using only oral anticoa-
gulation or antiplatelet drugs or a combination of these
medications were specifically allowed as considered
necessary by the responsible physician. This is in keep-
ing with the goal of the study to compare percutaneous
PFO closure against best medical treatment, meaning
medical treatment deemed optimal for the individual
patient by the responsible physician. The recommended
therapeutic range for patients who are orally anticoagu-
lated in this study was an international normalized ratio
(INR) of 2.0-3.0. A crossover from oral anticoagulation
to antiplatelet therapy with acetylsalicylic acid, ticlopi-
dine, or clopidogrel or vice versa was allowed within the
best medical treatment arm. The date of drug therapy
change and the reasons was documented in the case
record form (CRF). Furthermore, events leading to inter-
ruption of antithrombotic therapy or bleeding complica-
tions were recorded as adverse events in the follow-up
section of the CRF. Medical treatment was commenced
immediately after randomization, unless already en
route. Any events leading to interruption of antithrom-
botic therapy as well as any bleeding complications were
recorded as adverse events.
The statistical power of this study was based on the
population allocated to the best medical treatment
group as a whole. Although differences among the dif-
ferent antithrombotic regimens will be analyzed, the sta-
tistical power may be inadequate to allow firm
respective conclusions.
Adverse events
Risk of percutaneous PFO closure
The risks of percutaneous PFO closure using the
Amplatzer PFO Occluder consist of the risk of the
implantation procedure and the long-term risk of
the device itself. The implantation risks are similar to
those of other interventional cardiac procedures [20].
They include complications related to vascular access
(1-2%; e.g. bleeding, hematoma, need for transfusion),
cardiac perforation with or without tamponade (<1%)
[21-26], or air embolism (1-2%). The risks of stroke and
myocardial infarction are expected to be lower than
with coronary angiography which requires arterial
access. The risk of death is minimal.
Complications intrinsic to the PFO device include
device embolization (3-6%) primarily into the right cir-
culation. Usually, the device can be retrieved either per-
cutaneously, rarely surgery is needed. Other potential
hazards include thrombus formation in the implantation
equipment or on the device surface with the risk of sub-
sequent embolization, infective endocarditis, or device
collapse due to structural fatigue. Bleeding due to the
post implantation medical management is another
hazard.
Risk of medical treatment
The risks of medical treatment relate to adverse events
of antithrombotic therapy. Bleeding is the main compli-
cation of oral anticoagulant therapy with warfarin or
alike [27,28] and is influenced by the intensity of antic-
oagulation and the concomitant use of antiplatelet
agents. The bleeding risk appears higher in patients with
a history of prior stroke or gastrointestinal bleeding.
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Intracranial hemorrhage is estimated to occur with an
incidence of 0.5% per year in patients on oral anticoagu-
lant therapy with coumadin. Another important, but
uncommon adverse effect of coumadin is skin necrosis.
Furthermore many other medications and food compo-
nents interfere with the metabolism of oral anticoagu-
lants, potentiating or inhibiting their effects.
The principal adverse effects of acetylsalicylic acid are
prolonged bleeding due to inhibition of platelet func-
tion, stomach irritation, gastritis, or gastrointestinal
bleeding. These complications are rare and the thera-
peutic benefit of acetylsalicylic acid outweighs these
potential adverse advents. Acetylsalicylic acid increases
the risk for intracranial hemorrhage minimally. In case
of intolerance to acetylsalicylic acid, ticlopidine or clopi-
dogrel were used. Adverse event definitions for both
treatment modalities are shown in Appendix 4.
Statistical Methods
The working hypothesis of this study postulates a reduc-
tion in the annual incidence of recurrent thromboem-
bolic events from 3% per year to ≤1% per year in
patients with percutaneous closure of the PFO. With an
overall sample size of 410, the power will be 80% at an
a-level of 0.0492 (allowing for one interim analysis)
under the following assumptions: mean follow-up time
4.5 years; successful closure of the PFO in 95% of those
randomized to PFO closure; and annual rate of patients
lost to follow-up 0.5%. The comparability between the
two treatment groups will be tested with the two sample
t-test or Fischer’s exact test as appropriate, for continu-
ous covariates, and Pearson’s chi square test for catego-
rical variables. An adjusted alpha level of 0.01 will be
used as indication for an imbalance between the study
groups.
The data from all participating centers will be pooled
for the analysis of all primary and secondary endpoints
as well as adverse events. An intention-to-treat analysis
will be carried out retaining all the randomized study
participants irrespective of whether they received the
allocated treatment or not. Analysis of primary and sec-
ondary end points will be done using proportional
hazard models. Graphical representation and compari-
son of survival between the two intervention groups will
be presented using Kaplan Meier survival curves. Sec-
ondary analyses of these end points stratified by age,
(age ≥45 years vs. <45 years and presence or absence of
ASA) and effect modification by age and ASA will be
tested in multivariable modeling. The significance level
to reject the null hypothesis is set to 0.0492 (two-sided)
taking account of the planned interim analysis.
An interim analysis will be conducted after 2.5 years
of follow-up of the entire study population to detect an
important excess in benefit or risk of closure of the
PFO as compared to medical treatment. The significance
level to define statistically a significant excess or reduc-
tion in risk will be 0.0054 (two-sided) according to
O’Brian-Fleming boundaries. Data and Safety Monitor-
ing Board is entitled to interrupt the trial taking into
account both, clinical and statistical significance of
excess or reduction in risk.
Study organization
The study comprises the participating centres and an
organizing board structure that includes a Steering
Committee, a Data and Safety Monitoring Board, a Data
Coordinating Center, and a Statistical Core Center. Each
participating centre has a nominated research assistant
to supervise the study and organize local data collection.
This study is conducted in compliance with the Helsinki
Declaration and an ethical approval was given from the
responsible ethical committee of every participating
centre.
Discussion
In most people, a PFO will remain asymptomatic for
life. However, since the initial description of a fatal
stroke in a young woman linked to a PFO by Cohnheim
in 1877, PFO and ASA have been increasingly recog-
nized as potential mediators of several disease manifes-
tations, including paradoxical embolism with the
principal risk of cerebral or myocardial infarction, ortho-
static desaturation in the setting of the rare platypnoea-
orthodeoxia syndrome, refractory hypoxemia due to
right-to-left shunt in patients with right ventricular
infarction or severe pulmonary disease, neurological
decompression illness in divers, migraine with aura,
transient global amnesia, obstructive sleep apnea, and
high-altitude pulmonary edema.
Several case-control studies using contrast echocardio-
graphy showed a strong relation between the presence
of PFO and cryptogenic stroke in adults particularly
aged <55 years [29-34]. According to a meta-analysis
[35], in patients younger than 55 years, a PFO confers a
relative risk of 3 (95% CI 2 to 4) comparing ischemic
stroke with non-stroke control subjects, and a relative
risk of 6 (95% CI 4 to 10) comparing cryptogenic stroke
with control subjects with a known cause of stroke.
Medical treatment using antithrombotic drugs, percu-
taneous device closure, or surgical closure constitute
measures for secondary prevention against recurrent
embolic events in patients with PFO. To date, published
randomized comparisons between these modalities
regarding safety and efficacy are lacking.
At present, the most restrictive indications are applied
in the USA, where failed medical treatment for second-
ary stroke prevention constitutes the sole Food and
Drug Agency accepted indication for PFO closure with
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a plea to effect the treatment exclusively in the realm of
a randomized study [36].
Appendix 1: PC-trial endpoints
Primary composite endpoint
a. Death
1. Fatal stroke: a stroke deemed to have caused
death either directly by brain damage or indirectly
by some non-neurological complication.
2. Cardiovascular death: including sudden death,
myocardial infarction, circulatory failure, pulmonary
edema, heart failure and death due to any vascular
cause including aortic, mesenteric, or peripheral vas-
cular or embolic disease. An unwitnessed unsus-
pected death will be counted as sudden death.
3. Non-cardiovascular death: any death not classified
as fatal stroke or cardiovascular death.
b. Nonfatal stroke: any neurologic deficit lasting for
>24 hours.
1. Major stroke: a new neurologic deficit that per-
sists for more than 7 days and increases the NIH
Stroke Scale score by >4.
2. Minor stroke: a new neurologic deficit that either
resolves completely within 7 days or increased the
NIH Stroke Scale score by less than <3.
3. TIA: a transient ischemic attack is defined as a
temporary neurologic deficit presumably due to
reduced blood flow in a particular cerebral artery
lasting for <24 hours with complete resolution of the
neurologic deficit.
c. Peripheral embolism: any endorgan ischemia other
than in the brain caused by reduced blood flow in a parti-
cular artery and objectively documented by Duplex, com-
puted tomography (CT), MR imaging, or angiography.
Secondary endpoints
a. New arrhythmia: any rhythm disorder other than nor-
mal sinus rhythm, requiring either hospitalization or
pharmacologic or electrical therapy interventions.
b. Myocardial infarction: CK-MB >3 times the upper
limit of normal and present in two separate blood sam-
ples or new pathological Q-waves in at least two contig-
uous leads with any elevated CK-MB.
c. Rehospitalization related to PFO or its treatment:
>24 hour in-hospital stay, which becomes necessary for
the management of complications related either to the
PFO or antithrombotic therapy.
d. Device problems (dislodgment, structural failure,
infection, thrombosis etc.)
e. Bleeding complications related to antithrombotic
therapy will be classified as severe, if requiring any
blood transfusion, and minor, if not requiring blood
transfusions.
Appendix 2: PC-trial inclusion criteria
a. Age <60 years old
b. Presence of PFO (with or without ASA) documen-
ted by TEE with a right-to-left shunt during the bubble
test or color Doppler flow imaging either spontaneously
or with a Valsalva or cough maneuver.
c. Ischemic stroke verified clinically and neuroradiolo-
gically by magnetic resonance, computed tomography or
angiography in the absence of another identifiable cause
of stroke (see exclusion criteria).
d. Symptoms of TIA and neuroradiologically identified
intracranial ischemic lesion in the absence of another
identifiable cause of stroke (see exclusion criteria).
e. Clinically and radiologically verified extracranial
peripheral thromboembolism in the absence of another
identifiable cause of thromboembolism (see exclusion
criteria).
f. Sufficient recovery from the thromboembolic index
event to allow independent daily activities.
g. The physician implanting the device in case of allo-
cation to percutaneous PFO closure agrees to implant
an Amplatzer PFO Occluder Other commercially avail-
able devices for percutaneous PFO closure are not to be
used in this study.
Appendix 3: PC-trial exclusion criteria
a. Any identifiable cause for the thromboembolic event
other than PFO. The following causes must be specifi-
cally excluded in all patients enrolled in this study:
Cardiac: mural thrombus, dilated cardiomyopathy,
prosthetic heart valve, mitral stenosis, bacterial and non-
bacterial endocarditis, cardiac myxoma, atherosclerosis
of the aorta, chronic or paroxysmal atrial fibrillation. (12
lead ECG, transesophageal echocardiography, >24-hour
ECG monitoring in case of suspected arrhythmias).
Peripheral Vascular System: significant atherosclerosis
or dissection of the aorta (TEE, MR, CT).
Cerebrovascular System: clinically relevant athero-
sclerosis or dissection of the intra- and extracranial
arteries (Duplex ultrasound of the carotid arteries, con-
trast MR or CT head scan). Any preexisting neurological
disorder or significant intracranial disease (i.e. multiple
sclerosis, arteriovenous malformations, previous intra-
cranial hemorrhage).
Vasculitis: significant collagen vascular disease, giant
cell arteritis, vasculitis, systemic necrotizing vasculitis
(history, physical examination, erythrocyte sedimentation
rate, C-reactive protein, antinuclear antibodies).
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Hematologic: hyperviscosity syndromes (erythrocyto-
sis with hematocrit >50%, leucocytosis with white blood
cell count >150 000 per μl, thrombocytosis with plate-
lets >106 per μl, paraproteinemia), hypercoagulable
states (coagulation status including prothombin time,
INR, activated partial thromboplastin time, complete
blood cell count, serum protein electrophoresis, anticar-
diolipin antibodies)
b. Contraindication for chronic oral anticoagulant or
antiplatelet therapy:
1. severe bleeding disorder within past 3 months
prior to randomization: gastrointestinal bleeding,
gross hematuria, known coagulopathy, platelet
disorder.
2. significant retinopathy (hemorrhages, exudates)
3. significant intracranial disease
4. previous intracranial hemorrhage
c. Patients who are on chronic anticoagulant therapy
for another disease entity (e.g. prosthetic heart valve)
other than paradoxical embolism
d. Previous surgical or percutaneous PFO closure
e. Drug or alcohol abuse <48 hours prior to the
thromboembolic index event.
f. Septicemia or severe localized infection
g. Pregnancy
h. Severe central nervous system disease (seizure
disorder, inflammatory disease of the central nervous
system, severe disability from previous stroke, i.e.
Barthel-index <50, Modified Rankin scale >3)
i. No informed consent
j. Follow-up over the next 5 years not possible (i.e.
severe comorbid diseases with limited life expectancy,
unreliable patient etc).
Appendix 4: Possible adverse events with both
treatment modalities
PFO-device related adverse events
Major procedural complications
1. Death occurring within 24 hours of the procedure
due to a perioperative complication
2. Cardiac perforation with or without tamponade if
requiring pericardiocentesis or surgery
3. Device embolization as dislocation of the PFO
device from the atrial septum to another intravascular
region necessitating its percutaneous or surgical removal
4. Severe bleeding complication - vascular access site
injury requiring surgical correction or significant drop
in hemoglobin (>5 g/dl) or requiring transfusion.
5. Intraprocedural stroke (with symptoms persisting
for more than 24 hours)
Minor procedural complications
1. Cardiac arrhythmias: sustained cardiac arrhythmias
related to device implantation requiring electrical (direct
current countershock, pacing) or antiarrhythmic drug
therapy. Minor arrhythmias (nonsustained, not requiring
treatment) are not considered.
2. Cardiac perforation without need for treatment
3. Vascular access site complications
- local hematoma associated with a palpable mass >4
cm and hemoglobin drop >3 and <5 g/dl.
- arteriovenous fistula
- false aneurysm
4. Air embolism with symptoms persisting for >15
minutes but <24 hours
5. Complications necessitating device removal
6. Transient neurologic deficit (TIA) with complete
resolution within 24 hours
b. Nonprocedural complications All other adverse
events not related to the immediate device implantation
period (>24 hours after PFO closure) are considered
nonprocedural complications.
- death
- stroke
- peripheral embolism
- need for prolonged hospitalization or readmission
- bleeding complications
Adverse events related to antithrombotic therapy
- any event leading to interruption of antithrombotic
therapy
- bleeding complications related to antithrombotic
therapy
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